The latest market price and cost reference of Romiplostim in 2025

Romiplostim (also known as romiplostim), as a recombinant thrombopoietin receptor agonist, has been launched in China and is gradually entering clinical use. According to public information, as of 2025 , the price of its original imported version is about more than 2,000 yuan; at the same time, a domestic version has also been launched, and each domestically produced drug is roughly more than 1,000 yuan. This price range is significantly discounted from past overseas channels, which greatly reduces the financial burden on patients.

Judging from history and overseas prices, when loplastin was obtained through overseas channels in the past, the price was as high as about more than 9,000 to 10,000 yuan per tube.

Nowadays, domestic listing and medical insurance coverage have led to significant price reductions through formal channels, reducing patients' dependence on overseas purchasing channels. The Yaode website pointed out that after medical insurance reimbursement, patient payment costs dropped significantly. Medical insurance reimbursement is an important factor affecting actual expenses. Roprostim has been included in the national medical insurance catalog. There are still differences in medical insurance policies in different regions: reimbursement ratios, medication approval processes, reimbursement thresholds, etc. may vary from province to city. Therefore, patients should confirm local policies with the hospital pharmacy or medical insurance department before actually taking medication.

Despite the existing medical insurance coverage and significant price reductions, patients still need to pay attention to the following matters: First, due to supply and channel problems, some hospitals may be temporarily short of inventory; secondly, although medical insurance reimburses, there may still be a self-pay part, especially under different medical insurance levels and regional differences; finally, patients should fully communicate with the doctor about the treatment plan, frequency and cost of medication before starting medication, and retain relevant invoices and reimbursement vouchers to ensure compliance with medical insurance requirements. In short, in 2025 the economic accessibility of loplastin has been significantly improved compared to before, but the specific cost is still highly dependent on the region and medical insurance policies.

Reference materials:https://www.drugs.com/